Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2025 10:05 ET | Source: Boehringer Ingelheim Limited

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were...
October 17, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 2025

Monotherapy shows deep and durable responses in NSCLC and a best-in-class safety profile without thrombocytopeniaCompletion of monotherapy dose escalation part of the study will be followed by the...
October 16, 2025 20:23 ET | Source: Junshi Biosciences

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

FDA has approved Junshi Biosciences' IND for a Phase 2/3 clinical study of JS207 (PD-1/VEGF), for the neoadjuvant treatment of NSCLC
October 14, 2025 08:10 ET | Source: Candel Therapeutics

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell...
September 25, 2025 00:08 ET | Source: Immuneering Corporation

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A
September 24, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Placement to Sanofi
September 24, 2025 16:01 ET | Source: Immuneering Corporation

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
September 24, 2025 08:01 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE...
September 16, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
September 10, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Septe